- Home
- USIO vs NRXP Comparison
USIO vs NRXP Comparison
Compare USIO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- NRXP
- Stock Information
- Founded
- USIO 1998
- NRXP 2015
- Country
- USIO United States
- NRXP United States
- Employees
- USIO N/A
- NRXP N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- NRXP Health Care
- Exchange
- USIO Nasdaq
- NRXP Nasdaq
- Market Cap
- USIO 50.2M
- NRXP 58.5M
- IPO Year
- USIO N/A
- NRXP N/A
- Fundamental
- Price
- USIO $1.46
- NRXP $2.84
- Analyst Decision
- USIO Strong Buy
- NRXP Strong Buy
- Analyst Count
- USIO 1
- NRXP 5
- Target Price
- USIO $4.00
- NRXP $31.40
- AVG Volume (30 Days)
- USIO 88.1K
- NRXP 562.9K
- Earning Date
- USIO 11-05-2025
- NRXP 08-18-2025
- Dividend Yield
- USIO N/A
- NRXP N/A
- EPS Growth
- USIO N/A
- NRXP N/A
- EPS
- USIO 0.11
- NRXP N/A
- Revenue
- USIO $83,851,606.00
- NRXP N/A
- Revenue This Year
- USIO $8.66
- NRXP N/A
- Revenue Next Year
- USIO $13.32
- NRXP $231.16
- P/E Ratio
- USIO $13.42
- NRXP N/A
- Revenue Growth
- USIO 2.05
- NRXP N/A
- 52 Week Low
- USIO $1.24
- NRXP $1.10
- 52 Week High
- USIO $2.92
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- USIO 44.97
- NRXP 56.21
- Support Level
- USIO $1.43
- NRXP $2.26
- Resistance Level
- USIO $1.55
- NRXP $2.81
- Average True Range (ATR)
- USIO 0.07
- NRXP 0.23
- MACD
- USIO -0.00
- NRXP 0.04
- Stochastic Oscillator
- USIO 44.44
- NRXP 78.38
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.